Physician profile
Douglas E Roberts
NPI 1083698062
$22,747.07
in general payments reported to CMS, 2019-2025
38 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,476 · 2020: $5,562 · 2021: $3,074 · 2022: $3,229 · 2023: $3,200 · 2024: $3,206.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,392 · Education: $14.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,391.67 |
| Education | $14.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $4,716.03 | 2019-2024 | |
| Amgen INC. | $3,271.24 | 2019-2024 | Enbrel, Otezla, Tavneos |
| Janssen Biotech, INC. | $2,242.81 | 2019-2024 | Tremfya, Simponi Aria, Remicade |
| Abbvie INC. | $2,185.19 | 2019-2024 | Rinvoq |
| Horizon Therapeutics Plc | $1,395.94 | 2019-2023 | Krystexxa |
| Glaxosmithkline, LLC. | $1,157.11 | 2019-2024 | Benlysta |
| Pfizer INC. | $905.44 | 2019-2024 | |
| Mallinckrodt Hospital Products INC. | $748.25 | 2020-2024 | Acthar |
| Ucb, INC. | $733.07 | 2019-2024 | Cimzia, Bimzelx |
| E.R. Squibb & Sons, L.L.C. | $578.61 | 2019-2024 | Orencia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $542.07 | 2020-2024 | Ofev, Cyltezo |
| Genentech USA, INC. | $468.86 | 2019-2024 | Actemra |
| Medexus Pharma, INC. | $397.31 | 2019-2020 | |
| Fresenius Kabi USA, LLC | $377.72 | 2023-2024 | Idacio |
| Ani Pharmaceuticals, INC. | $371.78 | 2022-2024 | Purified Cortrophin Gel |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $346.69 | 2019 | |
| Radius Health, INC. | $328.72 | 2019-2024 | Tymlos |
| Alexion Pharmaceuticals, INC. | $244.94 | 2019-2023 | Strensiq |
| Hikma Pharmaceuticals USA | $230.53 | 2019-2021 | |
| Antares Pharma, INC. | $212.02 | 2019-2021 | |
| Aurinia Pharma U.S., INC. | $199.40 | 2021-2024 | Lupkynis |
| Genzyme Corporation | $190.21 | 2019-2024 | |
| Lilly USA, LLC | $180.48 | 2019-2023 | Taltz |
| Mallinckrodt Enterprises LLC | $179.86 | 2019 | |
| Genentech, INC. | $145.85 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $99.69 | 2021-2024 | Saphnelo |
| Actelion Pharmaceuticals US, INC. | $58.45 | 2020-2021 | |
| Eyevance Pharmaceuticals LLC | $45.93 | 2021 | |
| Scilex Pharmaceuticals INC. | $45.38 | 2024 | |
| Ultragenyx Pharmaceutical INC. | $24.16 | 2021 | |
| Daiichi Sankyo INC. | $21.39 | 2019 | |
| Ironwood Pharmaceuticals, INC | $16.36 | 2020 | |
| Eisai INC. | $16.28 | 2021 | |
| Sanofi Pasteur INC. | $15.66 | 2019 | |
| Zyla Life Sciences, INC. | $14.30 | 2019 | |
| Merck Sharp & Dohme LLC | $14.14 | 2019 | |
| Ibsa Pharma INC. | $13.65 | 2024 | Licart, Tirosint |
| Organon LLC | $11.55 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Roberts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.